Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroaki Taguchi

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
The Journal of Biological Chemistry|March 1, 2015
Specific amyloid β clearance by a catalytic antibody constructStephanie A Planque, Yasuhiro Nishiyama, Sari Sonoda, et al.
Modern Rheumatology|July 8, 2025
Vaccine-related environments and patient preferences in Japanese patients with autoimmune rheumatic diseasesKenji Oku, Hidehiro Yamada, Tatsuyoshi Ikenoue, et al.
Clinical and Experimental Rheumatology|September 26, 2025
Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE studyYohei Hosokawa, Yusuke Yoshida, Hiroya Tamai, et al.
The Lancet. Rheumatology|January 22, 2024
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|October 4, 2024
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|January 28, 2025
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
The Journal of Biological Chemistry|March 1, 2015
Specific amyloid β clearance by a catalytic antibody constructStephanie A Planque, Yasuhiro Nishiyama, Sari Sonoda, et al.
Modern Rheumatology|July 8, 2025
Vaccine-related environments and patient preferences in Japanese patients with autoimmune rheumatic diseasesKenji Oku, Hidehiro Yamada, Tatsuyoshi Ikenoue, et al.
Clinical and Experimental Rheumatology|September 26, 2025
Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE studyYohei Hosokawa, Yusuke Yoshida, Hiroya Tamai, et al.
The Lancet. Rheumatology|January 22, 2024
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|October 4, 2024
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|January 28, 2025
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Pageof 7